{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:56:00Z","timestamp":1770220560252,"version":"3.49.0"},"reference-count":122,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Gene expression-guided drug repurposing has emerged as a strategy to identify new therapy opportunities by associating disease transcriptional signatures with drug-induced gene expression profiles. This is relevant for prostate and bladder cancers, which have high molecular heterogeneity and therapy resistance limits for their standard treatment regimens. Antiretrovirals have been of great interest as repurposed candidates for these cancers due to their various effects on cancer cell pathways. The objective of this review is to assess the principles, applications, and challenges of this approach, with emphasis on antiretrovirals. Methods: This review summarizes published literature on gene expression-based drug repurposing methodologies, including signature reversion, pathway level analysis, and validation studies. Studies applying these concepts to prostate and bladder cancer were analyzed, and evidence of antiretroviral repurposing for cancer therapy was assessed based on transcriptomic alterations, pathway perturbation, and preclinical outcomes. Results: Transcriptomic-driven studies identified several drug candidates capable of modulating gene expression associated with therapy resistance, tumor progression, and cell stress responses. The anticancer effects of antiretrovirals were shown to be related to cell cycle arrest, apoptosis, metabolic alterations, and proteostasis. Nonetheless, transcriptomic responses are highly context-dependent and can be influenced by tumor subtype and experiment and treatment conditions. Off-target effects can also complicate mechanism interpretation. Conclusions: Gene expression\u2013guided drug repurposing enables the systematic prioritization of clinically actionable candidates by matching disease and drug transcriptional signatures, but successful translation will require the integration of other omics results, careful model selection, and the development of clinically relevant biomarkers to support mechanism-informed repurposing. Translation will depend on subtype-aware signature matching, integration with complementary omics, and biomarker-backed validation to support precision deployment.<\/jats:p>","DOI":"10.3390\/genes17020184","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:48:08Z","timestamp":1770025688000},"page":"184","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8202-1459","authenticated-orcid":false,"given":"Mariana","family":"Pereira","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"ICBAS\u2014School of Medicine and Biomedical Sciences, University of Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","article-title":"Drug rechanneling: A novel paradigm for cancer treatment","volume":"68","author":"Kaushik","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug Repurposing: An Effective Tool in Modern Drug Discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/uro4030012","article-title":"Bladder Cancer Basic Study and Current Clinical Trials","volume":"4","author":"Godlewski","year":"2024","journal-title":"Uro"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/OP-25-00037","article-title":"Challenges in the Management of Advanced Prostate Cancer","volume":"21","author":"Ozay","year":"2025","journal-title":"JCO Oncol. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/em.20195","article-title":"Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors","volume":"48","author":"Olivero","year":"2007","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.21873\/anticanres.14564","article-title":"Azidothymidine (AZT) Inhibits Proliferation of Human Ovarian Cancer Cells by Regulating Cell Cycle Progression","volume":"40","author":"Hsieh","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_7","first-page":"2341","article-title":"Potent Growth Inhibitory Activity of Zidovudine on Cultured Human Breast Cancer Cells and Rat Mammary Tumors","volume":"57","author":"Wagner","year":"1997","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Turanli, B., Gr\u00f8tli, M., Boren, J., Nielsen, J., Uhlen, M., Arga, K.Y., and Mardinoglu, A. (2018). Drug Repositioning for Effective Prostate Cancer Treatment. Front. Physiol., 9.","DOI":"10.3389\/fphys.2018.00500"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Daftari, M., Ramsoomair, C.K., Aaronson, D., Seetharam, D., Andreae, E.A., Wright, L., Han, S., Chandar, J., Lu, V., and Govindarajan, V. (2025). Synergistic Treatment with Antiretrovirals and Laser Interstitial Thermal ThErapy (STARLITE) for unresectable glioblastoma: A phase 1 study protocol. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0328204"},{"key":"ref_10","first-page":"e67776","article-title":"Efavirenz: New Hope in Cancer Therapy","volume":"16","author":"Elango","year":"2024","journal-title":"Cureus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/JTO.0b013e31820c9e3c","article-title":"The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin","volume":"6","author":"Srirangam","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/s41598-025-87676-3","article-title":"Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle","volume":"15","author":"Nair","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1756-9966-32-38","article-title":"The antiretroviral agent saquinavir enhances hTERT expression and telomerase activity in human T leukaemia cells in vitro","volume":"32","author":"Adamo","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41386-020-0752-6","article-title":"Signature-based approaches for informed drug repurposing: Targeting CNS disorders","volume":"46","author":"Shukla","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhong, X., Wei, Q., Tiwari, A., Wang, Q., Tan, Y., Chen, R., Yan, Y., Cox, N.J., and Li, B. (2025). A Genetics-guided Integrative Framework for Drug Repurposing: Identifying Anti-hypertensive Drug Telmisartan for Type 2 Diabetes. medRxiv.","DOI":"10.1101\/2025.03.22.25324223"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.isci.2019.04.039","article-title":"Perturbational Gene-Expression Signatures for Combinatorial Drug Discovery","volume":"15","author":"Huang","year":"2019","journal-title":"iScience"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"106867","DOI":"10.1016\/j.compbiomed.2023.106867","article-title":"Methodology to identify a gene expression signature by merging microarray datasets","volume":"159","author":"Fajarda","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Chalkioti, M., Papikinos, T., Krokidis, M.G., Vlamos, P., and Exarchos, T.P. (2025). Leveraging Gene Expression Data for Drug Repurposing in Schizophrenia: A Signature Reversion Approach. Drugs Drug Candidates, 4.","DOI":"10.3390\/ddc4040049"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/2211-5463.13796","article-title":"Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates","volume":"14","author":"Fisher","year":"2024","journal-title":"FEBS Open Bio"},{"key":"ref_21","unstructured":"Ganesan, K., Goyal, A., and Roane, D. (2025). Bisphosphonate. StatPearls, StatPearls Publishing LLC.. StatPearls Publishing Copyright \u00a9 2025."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JNN.0000000000000625","article-title":"Nimodipine in Clinical Practice: A Pharmacological Update","volume":"54","author":"Clough","year":"2022","journal-title":"J. Neurosci. Nurs."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mahdi-Esferizi, R., Shiasi, Z., Heidari, R., Najafi, A., Mahmoudi, I., Elahian, F., and Tahmasebian, S. (2024). Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer. BMC Cancer, 24.","DOI":"10.1186\/s12885-024-12142-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"bbac490","DOI":"10.1093\/bib\/bbac490","article-title":"Validation of transcriptome signature reversion for drug repurposing in oncology","volume":"24","author":"Koudijs","year":"2022","journal-title":"Brief. Bioinform."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41386-024-01805-6","article-title":"Network-based drug repurposing for schizophrenia","volume":"49","author":"Truong","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13059-020-1949-z","article-title":"Robustness and applicability of transcription factor and pathway analysis tools on single-cell RNA-seq data","volume":"21","author":"Holland","year":"2020","journal-title":"Genome Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand","year":"2019","journal-title":"Nat. Protoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","author":"Milacic","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wu, C., Gudivada, R.C., Aronow, B.J., and Jegga, A.G. (2013). Computational drug repositioning through heterogeneous network clustering. BMC Syst. Biol., 7.","DOI":"10.1186\/1752-0509-7-S5-S6"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/omi.2022.0026","article-title":"A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression","volume":"26","author":"Cong","year":"2022","journal-title":"Omics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciaa1046","article-title":"Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus","volume":"72","author":"Silverberg","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-Associated Cancers and Related Diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"International Collaboration on HIV and Cancer (2000). Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst., 92, 1823\u20131830.","DOI":"10.1093\/jnci\/92.22.1823"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/COH.0000000000000025","article-title":"Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk","volume":"9","author":"Borges","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3727\/096504017X14905635363102","article-title":"Different Cell Cycle Modulation in SKOV-3 Ovarian Cancer Cell Line by Anti-HIV Drugs","volume":"25","author":"Perna","year":"2017","journal-title":"Oncol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.21873\/anticanres.13793","article-title":"Lopinavir-Ritonavir Combination Induces Endoplasmic Reticulum Stress and Kills Urological Cancer Cells","volume":"39","author":"Okubo","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.31083\/j.fbl2907242","article-title":"Antiretroviral Drugs Impact Autophagy: Opportunities for Drug Repurposing","volume":"29","author":"Cheney","year":"2024","journal-title":"Front. Biosci."},{"key":"ref_39","first-page":"1335","article-title":"Matrix metalloproteinases are involved in both type I (apoptosis) and type II (autophagy) cell death induced by sodium phenylacetate in MDA-MB-231 breast tumour cells","volume":"29","author":"Augustin","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.antiviral.2009.07.017","article-title":"Pharmacokinetics and drug-drug interactions of antiretrovirals: An update","volume":"85","author":"Dickinson","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"De Bellis, E., Donnarumma, D., Zarrella, A., Mazzeo, S.M., Pagano, A., Manzo, V., Mazza, I., Sabbatino, F., Corbi, G., and Pagliano, P. (2025). Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17010031"},{"key":"ref_42","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/auto.5224","article-title":"Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy","volume":"4","author":"Gills","year":"2008","journal-title":"Autophagy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zha, W., Wang, G., Xu, W., Liu, X., Wang, Y., Zha, B.S., Shi, J., Zhao, Q., Gerk, P.M., and Studer, E. (2013). Inhibition of P-Glycoprotein by HIV Protease Inhibitors Increases Intracellular Accumulation of Berberine in Murine and Human Macrophages. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054349"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2015.04.027","article-title":"Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway","volume":"364","author":"Xiang","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Singh, A.K., and Das, K. (2022). Insights into HIV-1 Reverse Transcriptase (RT) Inhibition and Drug Resistance from Thirty Years of Structural Studies. Viruses, 14.","DOI":"10.3390\/v14051027"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1038\/s41467-024-48066-x","article-title":"Identification and characterization of small molecule inhibitors of the LINE-1 retrotransposon endonuclease","volume":"15","author":"Jogl","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/bcp.70113","article-title":"Approaches to repurposing reverse transcriptase antivirals in cancer","volume":"91","author":"Head","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: Genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat. Rev. Urol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4103\/1008-682X.178852","article-title":"Clinical variability and molecular heterogeneity in prostate cancer","volume":"18","author":"Shoag","year":"2016","journal-title":"Asian J. Androl."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Irham, L.M., Adikusuma, W., Afief, A.R., Khairi, S., Chong, R., Mufidah, S., Satria, R.D., Mugiyanto, E., Darmawi, D., and Amukti, D.P. (2025). Integrative genomic and bioinformatic prioritization of drug repurposing candidates for prostate cancer. BMC Pharmacol. Toxicol., 26.","DOI":"10.1186\/s40360-025-00983-3"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kim, I.W., Kim, J.H., and Oh, J.M. (2019). Screening of Drug Repositioning Candidates for Castration Resistant Prostate Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00661"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_55","first-page":"3","article-title":"Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel","volume":"7","author":"Wosikowski","year":"2024","journal-title":"Cancer Drug Resist."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/0008-5472.CAN-03-2677","article-title":"HIV-1 Protease Inhibitor, Ritonavir: A Potent Inhibitor of CYP3A4, Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo","volume":"64","author":"Ikezoe","year":"2004","journal-title":"Cancer Res."},{"key":"ref_57","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Pereira, M., and Vale, N. (2022). Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012240"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pereira, M., and Vale, N. (2025). Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz in Prostate and Bladder Cancer. Pharmaceuticals, 18.","DOI":"10.3390\/ph18091404"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"200911","DOI":"10.1016\/j.omton.2024.200911","article-title":"Drug repurposing screen targeting PARP identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer","volume":"32","author":"Matthews","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Carlini, F., Ridolfi, B., Molinari, A., Parisi, C., Bozzuto, G., Toccacieli, L., Formisano, G., De Orsi, D., Paradisi, S., and Grober, O.M. (2010). The reverse transcription inhibitor abacavir shows anticancer activity in prostate cancer cell lines. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014221"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/srep09698","article-title":"Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer","volume":"5","author":"Guan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/pros.20923","article-title":"Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo","volume":"69","author":"Landriscina","year":"2009","journal-title":"Prostate"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 315\u2013322.","DOI":"10.1038\/nature12965"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jmoldx.2024.08.005","article-title":"A Versatile and Upgraded Version of the LundTax Classification Algorithm Applied to Independent Cohorts","volume":"26","author":"Cotillas","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40164-025-00682-z","article-title":"Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases","volume":"14","author":"Bernardo","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hu, X., Li, G., and Wu, S. (2022). Advances in Diagnosis and Therapy for Bladder Cancer. Cancers, 14.","DOI":"10.3390\/cancers14133181"},{"key":"ref_70","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100938","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mokou, M., Lygirou, V., Angelioudaki, I., Paschalidis, N., Stroggilos, R., Frantzi, M., Latosinska, A., Bamias, A., Hoffmann, M.J., and Mischak, H. (2020). A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients\u2019 Omics Signatures. Cancers, 12.","DOI":"10.3390\/cancers12123519"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/cas.13242","article-title":"Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation","volume":"108","author":"Sato","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3727\/096504017X14957929842972","article-title":"Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress","volume":"26","author":"Sato","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-199937010-00004","article-title":"Intravesical drug delivery. Pharmacokinetic and clinical considerations","volume":"37","author":"Highley","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3233\/BLC-160056","article-title":"The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer","volume":"2","author":"Douglass","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s11095-008-9566-7","article-title":"Intravesical treatments of bladder cancer: Review","volume":"25","author":"Shen","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40266-023-01009-5","article-title":"Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options","volume":"40","author":"Ganguly","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e13189","DOI":"10.15252\/emmm.202013189","article-title":"Functional genomics approaches to improve pre-clinical drug screening and biomarker discovery","volume":"13","author":"Nguyen","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41698-025-00832-w","article-title":"Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine","volume":"9","author":"Mann","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cels.2020.04.007","article-title":"CELLector: Genomics-Guided Selection of Cancer In Vitro Models","volume":"10","author":"Najgebauer","year":"2020","journal-title":"Cell Syst."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Siranosian","year":"2018","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Jacob, A., Raj, R., Allison, D.B., and Myint, Z.W. (2021). Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. Cancers, 13.","DOI":"10.20944\/preprints202110.0016.v1"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"eabn4118","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"Laajala","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.eururo.2024.05.026","article-title":"Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response","volume":"86","author":"Merrill","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1158\/0008-5472.CAN-18-0989","article-title":"The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel","volume":"78","author":"Monks","year":"2018","journal-title":"Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Ji, R.R., de Silva, H., Jin, Y., Bruccoleri, R.E., Cao, J., He, A., Huang, W., Kayne, P.S., Neuhaus, I.M., and Ott, K.H. (2009). Transcriptional profiling of the dose response: A more powerful approach for characterizing drug activities. PLoS Comput. Biol., 5.","DOI":"10.1371\/journal.pcbi.1000512"},{"key":"ref_91","first-page":"44","article-title":"Resistance signatures manifested in early drug response across cancer types and species","volume":"8","author":"Ruoff","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s42003-020-01302-8","article-title":"Network integration and modelling of dynamic drug responses at multi-omics levels","volume":"3","author":"Selevsek","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Loos, N.H.C., Beijnen, J.H., and Schinkel, A.H. (2022). The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179866"},{"key":"ref_94","first-page":"346","article-title":"The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 Infection","volume":"36","author":"Schafer","year":"2011","journal-title":"Pharm. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12981-024-00694-5","article-title":"Factors associated with oxidative stress in virologically suppressed people living with HIV on long-term antiretroviral therapy","volume":"21","author":"Lombardi","year":"2024","journal-title":"AIDS Res. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Smith, R.L., Tan, J.M.E., Jonker, M.J., Jongejan, A., Buissink, T., Veldhuijzen, S., van Kampen, A.H.C., Brul, S., and van der Spek, H. (2017). Beyond the polymerase-\u03b3 theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0187424"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: The next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Chen, D., Liu, X., Yang, Y., Yang, H., and Lu, P. (2015). Systematic synergy modeling: Understanding drug synergy from a systems biology perspective. BMC Syst. Biol., 9.","DOI":"10.1186\/s12918-015-0202-y"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"He, Y., Tu, X., Xue, Y., Chen, Y., Ye, B., Li, X., Li, D., Zhong, Z., and Zhong, Q. (2025). CRISPR screening redefines therapeutic target identification and drug discovery with precision and scalability. J. Pharm. Anal., 101357.","DOI":"10.1016\/j.jpha.2025.101357"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"11795549251384582","DOI":"10.1177\/11795549251384582","article-title":"Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights","volume":"19","author":"Catalano","year":"2025","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Dimitrakopoulos, C., Hindupur, S.K., Colombi, M., Liko, D., Ng, C.K.Y., Piscuoglio, S., Behr, J., Moore, A.L., Singer, J., and Ruscheweyh, H.-J. (2021). Multi-omics data integration reveals novel drug targets in hepatocellular carcinoma. BMC Genom., 22.","DOI":"10.1186\/s12864-021-07876-9"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s43556-025-00340-0","article-title":"Multi-omics strategies for biomarker discovery and application in personalized oncology","volume":"6","author":"Jiang","year":"2025","journal-title":"Mol. Biomed."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Li, C., Tian, C., Zeng, Y., Liang, J., Yang, Q., Gu, F., Hu, Y., and Liu, L. (2022). Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3\u20134 NSCLC patients. BMC Med. Genom., 15.","DOI":"10.1186\/s12920-022-01184-1"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"bbae490","DOI":"10.1093\/bib\/bbae490","article-title":"DrugReSC: Targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer","volume":"25","author":"Liu","year":"2024","journal-title":"Brief. Bioinform."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Guan, S., Tu, M.J., and Yu, A.M. (2025). Practical Pharmacokinetic-Pharmacodynamic Models in Oncology. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17111452"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s13318-022-00765-w","article-title":"A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4\/5 and CYP2D6 Substrates","volume":"47","author":"Arora","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/psp4.13293","article-title":"Development of a physiologically-based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady-state conditions","volume":"14","author":"Ngo","year":"2025","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_110","first-page":"805","article-title":"Use of a physiologically based pharmacokinetic model to simulate drug\u2013drug interactions between antineoplastic and antiretroviral drugs","volume":"72","author":"Rajoli","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Chaira, T., Subramani, C., and Barman, T.K. (2023). ADME, Pharmacokinetic Scaling, Pharmacodynamic and Prediction of Human Dose and Regimen of Novel Antiviral Drugs. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041212"},{"key":"ref_113","first-page":"121","article-title":"Does large volume of distribution of lidocaine masks its systemic uptake from bladder?","volume":"11","author":"Tyagi","year":"2023","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/bcp.14476","article-title":"Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19","volume":"87","author":"Duffull","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","article-title":"Pharmacokinetics and dosage adjustment in patients with renal dysfunction","volume":"65","author":"Verbeeck","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/cc7093","article-title":"Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury","volume":"12","author":"Vilay","year":"2008","journal-title":"Crit. Care"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e2300603","DOI":"10.1200\/PO.23.00603","article-title":"Transcriptome-Based Prognostic and Predictive Biomarker Analysis of ENACT: A Randomized Controlled Trial of Enzalutamide in Men Undergoing Active Surveillance","volume":"8","author":"Ross","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e2300214","DOI":"10.1200\/PO.23.00214","article-title":"Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial","volume":"7","author":"Bitting","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"590626","DOI":"10.5402\/2012\/590626","article-title":"Pharmacodynamic modelling of biomarker data in oncology","volume":"2012","author":"Jackson","year":"2012","journal-title":"ISRN Pharmacol."},{"key":"ref_121","first-page":"596","article-title":"Gene expression-based pharmacodynamic biomarkers: The beginning of a new era in biomarker-driven anti-tumor drug development","volume":"10","author":"Mizuarai","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jnci\/djac210","article-title":"Design and reporting of phase III oncology trials with prospective biomarker validation","volume":"115","author":"Liang","year":"2023","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/2\/184\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:13:59Z","timestamp":1770182039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/2\/184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":122,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["genes17020184"],"URL":"https:\/\/doi.org\/10.3390\/genes17020184","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}